Navigation Links
Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Date:9/17/2013

CAMBRIDGE, England, September 17, 2013 /PRNewswire/ --

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications.

The Phase 3 studies are taking place in 19 major centres in France, Germany and the USA. They will recruit a total of 680 surgical patients at moderate to high risk of suffering PONV (patients with two or more of the four established "Apfel" risk factors for PONV). The trials compare the optimal dose of APD421 against placebo, the primary endpoint being no vomiting or retching and no requirement for anti-emetic rescue medication in the first 24 hours after surgery. The incidence and severity of nausea is also being studied. The studies are expected to complete in the first quarter of 2014.

APD421 comprises an intravenous formulation of the marketed dopamine D2 /D3 antagonist amisulpride, for the completely new, patent-protected, use of management of PONV. Acacia Pharma has generated highly positive Phase 2 clinical data on APD421, showing the optimal dose significantly reduced the PONV rate from 69% in the placebo group to 40% (p=0.006). APD421 was equally efficacious against both vomiting and nausea.

More than 130 million surgical procedures are performed worldwide each year, with PONV occurring in approximately 35% of cases in untreated patients and in 70% of those classed as high risk. Despite a number of anti-emetics in common use, many patients still suffer post-operatively with vomiting and especially nausea. About a third of those given prophylaxis for PONV still require rescue therapy in the first 6 hours after surgery, representing a substantial unmet medical need and commercial opportunity.

PONV offers Acacia Pharma a rapid development opportunity for APD421, owing to the acute nature of the condition, the large number of surgical procedures and the well-documented, benign safety profile of amisulpride, which has been widely used at much higher doses as an antipsychotic agent for 25 years. Amisulpride is also being developed by Acacia Pharma as APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV).

Dr Gabriel Fox, Acacia Pharma's Chief Medical Officer commented: "Our Phase 3 programme will give a very robust read-out on the efficacy and safety of APD421 compared to placebo in a broad population of surgical patients at risk of suffering PONV. We have been highly encouraged by the positive feedback from regulatory agencies and experienced clinical investigators in Europe and the US and look forward to seeing the data from these studies."

Acacia Pharma's CEO, Dr Julian Gilbert, added: "We are delighted to have initiated these Phase 3 studies so soon after securing our recent funding. The Phase 2 data we generated last year were excellent and we are confident of obtaining similar results in these bigger pivotal clinical studies."

About Acacia Pharma

Acacia Pharma (http://www.acaciapharma.com) is a pharmaceutical company focused on cancer supportive care, a rapidly developing commercial opportunity. The growth in the cancer supportive care market has been driven by the increasing incidence of cancer, the expansion of effective cancer therapies and the desire to improve both the effectiveness of treatment and the quality of life of cancer patients.

Acacia Pharma has generated a pipeline of product opportunities addressing a range of supportive care indications such as nausea & vomiting, xerostomia (dry mouth) and cachexia (muscle wasting) using a commercially driven approach to product discovery based on known drugs. This strategy leads to product opportunities with a higher probability of success and enables rapid clinical proof-of-concept. In addition, Acacia Pharma's products are expected to reach the market quickly given that they are based on the novel use of well-characterised pharmaceuticals.

Acacia Pharma is led by an experienced management team who have already successfully built and exited a number of life sciences companies. Management, Gilde Healthcare, Lundbeckfond Ventures, Novo A/S and Fidelity Biosciences are the Company's key shareholders. Acacia Pharma is based in Cambridge, UK.


'/>"/>
SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
4. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
5. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
6. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
7. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
8. Inovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
9. ViroPharma To Participate In The Stifel Nicolaus 2013 Healthcare Conference
10. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
11. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen ... Cell Collection: the first publicly available collection of ... cells that target key cellular structures with unprecedented ... Research, these powerful tools are a crucial first ... to better understand what makes human cells healthy ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
Breaking Biology Technology:
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):